Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AstraZeneca PLC (AZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. AstraZeneca files under Form 20-F for its annual report and uses Form 6-K to furnish current reports on material developments. These filings cover a broad range of topics, including clinical trial data, regulatory approvals, manufacturing investments, insider share transactions and changes in major shareholdings.
For investors following AstraZeneca’s oncology franchise, 6-K exhibits often reproduce detailed press releases on medicines such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan) and Imfinzi (durvalumab). These documents describe Phase 3 trial designs and endpoints, Breakthrough Therapy Designations, new indications in breast, lung, gastric, endometrial and ovarian cancers, and approvals in key markets. They can help readers understand how specific trials, such as DESTINY-Breast, TROPION, MATTERHORN and others, relate to AstraZeneca’s pipeline and commercial portfolio.
Filings also address Rare Diseases and Respiratory & Immunology, including updates on Koselugo (selumetinib) for neurofibromatosis type 1 and Saphnelo (anifrolumab) for systemic lupus erythematosus. Additional 6-Ks report on large capital projects, such as multi‑billion‑dollar manufacturing investments in Maryland and other US states, and on governance matters like director and senior executive share dealings or notifications of major institutional holdings.
On Stock Titan, these AZN filings are supplemented with AI-powered summaries that explain the key points of each document in plain language. Users can quickly see which filings relate to new indications, safety information, insider transactions (similar to Form 4-style disclosures for US issuers) or strategic investments. Real-time updates from EDGAR ensure that new AstraZeneca 6-Ks and other SEC submissions appear promptly, while AI insights help readers navigate lengthy technical exhibits such as clinical trial descriptions and multi-indication product updates.
AstraZeneca is asking shareholders to approve a Harmonised Listing Structure that would directly list AstraZeneca Shares on the NYSE while keeping listings on the London Stock Exchange and Nasdaq Stockholm. The proposal requires terminating the existing ADR programme, migrating settlement from CREST to DTC, and adopting amended articles to enable issuance of AstraZeneca DIs and, for certain restricted holdings, depositary receipts. The Board unanimously recommends the Resolution. The company highlights growth from $24.7bn revenue in 2015 to $54.1bn in 2024, core operating profit from $6.9bn to $16.9bn and core R&D spend from $5.6bn to $12.2bn; the US accounted for 43% of 2024 revenue and is forecast to be ~50% by 2030. Key dates: General Meeting 3 November 2025 and expected implementation by 2 February 2026.
AstraZeneca PLC reported a director/PDMR shareholding notification: Non-Executive Director Karen Knudsen acquired 9 American Depositary Shares (ADSs) on 9 September 2025 through reinvestment of the first interim dividend for the year ending 31 December 2025, which the company paid on 8 September 2025. Two ADSs equal one ordinary share of $0.25 each. The reported transaction price per ADS was $81.0499. The disclosure was made on 25 September 2025 and follows the EU Market Abuse Regulation reporting requirements.
AstraZeneca and Amgen's Tezspire (tezepelumab) received a positive CHMP recommendation for approval in the EU to treat adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The opinion was based on the Phase III WAYPOINT trial, which showed Tezspire reduced nasal polyp size by a mean of 2.08 points and nasal congestion by 1.04 points versus placebo at Week 52, with p<0.001 for both co-primary endpoints.
WAYPOINT data also reported a 98% near-elimination of the need for surgery and an 89% reduction in systemic corticosteroid use versus placebo. Safety and tolerability were consistent with the known profile. Regulatory reviews are ongoing in multiple other countries.
AstraZeneca reported positive interim Phase III results from the TULIP-SC trial showing subcutaneous Saphnelo (anifrolumab) met the pre-specified primary endpoint of reduced disease activity versus placebo in patients with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). The reduction in disease activity was measured by the BICLA at week 52, which requires improvement across organs without new flares. The interim analysis included the first 220 participants reaching week 52 from a randomised 1:1 trial of 367 participants receiving 120mg subcutaneous anifrolumab once weekly versus placebo on top of standard therapy. Safety was consistent with the known IV profile. Results are under regulatory review and slated for presentation at ACR Convergence 2025.
AstraZeneca reported top-line results from the RESOLUTE Phase III trial of Fasenra (benralizumab) in COPD. The trial randomized 689 participants with moderate to very severe COPD, all on background ICS/LABA/LAMA therapy and with elevated blood eosinophils (≥300 cells/µL). The primary endpoint—annualised rate of moderate or severe exacerbations in patients with ≥3 prior-year exacerbations—showed a numerical improvement with Fasenra but did not reach statistical significance. Safety and tolerability were consistent with Fasenra's known profile. AstraZeneca said it will analyse the full data set and share results with the scientific community. Fasenra is already approved for severe eosinophilic asthma and other eosinophilic conditions in multiple countries.
AstraZeneca reported its total voting rights and issued share capital. The company states that as at 31 August 2025 there are 1,550,692,963 ordinary shares of US$0.25 each carrying voting rights, with no shares held in treasury. This figure is presented so shareholders can use it as the denominator to determine whether they must notify changes in their holdings under the UK Disclosure and Transparency Rules.
The notice is a routine transparency disclosure and does not include financial results, transactions, or changes to capital structure beyond the voting‑rights count.
AstraZeneca issued a correction to a previously announced TR-1 notification. The Company states that a TR-1 submitted by The Capital Group Companies, Inc. and announced on 26 August 2025 was provided in error and should be disregarded. Shareholders are instead directed to the TR-1 notification relating to Capital Group that AstraZeneca announced on 21 August 2025, available via the referenced RNS link. The notice is administrative and clarifies which prior disclosure is the valid notification.
AstraZeneca PLC filed a foreign issuer report showing that an investor group linked to The Capital Group Companies, Inc. has crossed a key ownership threshold in the company.
According to the notification, Capital Group now holds 77,684,561 voting rights in AstraZeneca, equal to
AstraZeneca PLC furnished a Form 6-K reporting a notification of major holdings showing that The Capital Group Companies, Inc. and its affiliated investment managers crossed the 5% ownership threshold on 20-Aug-2025. The filing shows a resulting position of 77,500,852 shares, representing 5.009591% of voting rights, plus 14,685,540 depository receipts held indirectly (reported as 0.947037% indirect voting rights).
The disclosure explains the asset managers manage these shares on behalf of discretionary client accounts and that neither CGC nor its affiliates hold the shares for their own account. The Form 6-K is a routine, regulatory notification of significant institutional ownership rather than a corporate action by AstraZeneca.
AstraZeneca PLC reported a notification that its Executive Director and Chief Financial Officer, Aradhana Sarin, executed a sale of the company’s ordinary shares on